Corrigendum to 'Should treatment of low-level rifampicin mono-resistant tuberculosis be different?' [JCTUBE 23 (2021) 100241]

J Clin Tuberc Other Mycobact Dis. 2021 May 13:24:100245. doi: 10.1016/j.jctube.2021.100245. eCollection 2021 Aug.

F A Gopie^{1

2}, E Commiesie³, W C M de Lange⁴, D van Soolingen⁵, S G S Vreden¹, G de Vries⁶

¹ Academic Hospital Paramaribo, Paramaribo, Suriname.
² Faculty of Medical Sciences, Anton de Kom University of Suriname, Paramaribo, Suriname.
³ National Tuberculosis Program, Paramaribo, Suriname.
⁴ Department Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, The Netherlands.
⁵ National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
⁶ Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Abstract

[This corrects the article DOI: 10.1016/j.jctube.2021.100241.].